Wilson Sonsini Reps Fluidigm In $207M DVS Sciences Deal

Law360, New York (January 29, 2014, 6:38 PM EST) -- Biotech tools company Fluidigm Corp. has signed a deal to buy DVS Sciences Inc. for $207.5 million, strengthening its portfolio in single-cell analysis technology, the company said Wednesday.

Fluidigm said it has come to a definitive agreement to acquire DVS in a cash and stock deal, creating a company with a comprehensive portfolio of biotechnologies. Fluidigm is funding the cash portion of the acquisition with proceeds from a proposed convertible notes offering, the company said. The deal is expected to close next month, after which DVS...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.